Vorlesungsankündigung Blockseminar/Lecture announcement winter term 2020/21 For all students enrolled in MSc Chemistry, MSc Biology, Pharmacy, MSc Biotechnology or related advanced studies, and Chemistry/Pharmacy/Biology PhD students

Antibiotics: Current situation and future perspectives Prof. Dr. Peter Hammann, former Sanofi, Evotec Consultant for Antibiotic Research, Honorary Professor at University

Contents: The current global situation of bacterial infections, resistance and treatment will be discussed and available antibiotic classes will be analyzed. This will include the chemistry, biochemistry and biology of different classes and the R&D process for specific representatives will be outlined in more detail. Furthermore, the antibiotic pipeline and new approaches will be presented, to explain the trends in anti- biotic R&D and their impact on patients in the future.

Course language: English

The block seminar will take place online via zoom on the following days: March 8th: 9:00-12:00 and 13:00-16:00 March 9th: 9:00-12:00 and 13:00-16:00 March 10th: 9:00-12:30

Please register by email with Christina Decker [email protected] by March 6, 2021.

Peter Hammann joined Hoechst AG in 1986 in the area of infectious diseases. In 1995, he moved to Bombay, as head of research Hoechst, India. After returning to Germany 1997, he was the core research, department of Hoechst Marion Roussel in Frankfurt. 2000 he moved to New Jersey, USA as head of lead generation for Aventis (merger of HMR and Roussel Uclaf.) Being back in Frankfurt in 2005 after Sanofi merged with Aventis, he was one of the key leaders to rebuild infectious disease (ID) research within of the new company. As head of external opportunities for ID at Sanofi, he completed several major key research cooperation agreements and licensing in this field.

Since 2014, he was leading the Sanofi-Fraunhofer natural product center, a public private partnership (PPP), with a major focus on novel antibiotics. After the transfer of ID from Sanofi to Evotec in July 2018, he joined Evotec as SVP Infectious Diseases. In June 2020, he started his part time retirement program and works as a consultant for antibiotic and natural product research.

He is member of several international committees as scientific advisor, for example in the council of the Robert-Koch-Foundation, the research initiative Infect Control 2020, the Bavarian AMR initiative Bayresq, the Research Campus middle Hessen as well the HIPS center in Saarbrücken. Furthermore, he is advising startup companies in the field of anti-infectives.

Peter Hammann received his diploma in biochemistry from the technical University of Darmstadt in 1982 and his doctoral degree in organic chemistry from the University of in 1985. He completed his habilitation in medicinal chemistry in 1992 at the Veterinary , where he was lecturing for more than 20 years as an adjunct Professor. Since 2016, he is Honorary Professor at the Justus-Liebig- and since 2020 Honorary Professor at the .